Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 17/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 13/20 | 1.00 |
| ▸ | HPGD | P15428 | 8/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 9/20 | 0.83 |
| ▸ | GAA | P10253 | 1/20 | 0.81 |
| ▸ | RAB9A | P51151 | 1/20 | 0.69 |
| ▸ | MAPT | P10636 | 1/20 | 0.59 |
| ▸ | IDE | P14735 | 1/20 | 0.59 |
| ▸ | MPI | P34949 | 1/20 | 0.59 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.59 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15375702 | 0.91 | KDM4E (1.00) | KDM4EALDH1A1HPGDHSD17B10GAA | |
| SCHEMBL2754183 | 0.89 | KDM4E (1.00) | KDM4EALDH1A1HPGDHSD17B10GAA | |
| SCHEMBL12204302 | 0.88 | KDM4E (1.00) | KDM4EALDH1A1HPGDHSD17B10GAA | |
| SCHEMBL10050059 | 0.87 | KDM4E (0.77) | KDM4EALDH1A1HPGDHSD17B10GAA | |
| SCHEMBL7120420 | 0.80 | HSD17B10 (0.74) | KDM4EALDH1A1HPGDHSD17B10GAA | |
| SCHEMBL29722594 | 0.79 | RAB9A (0.77) | KDM4EALDH1A1HPGDHSD17B10GAA | |
| SCHEMBL15338397 | 0.79 | RAB9A (0.77) | KDM4EALDH1A1HPGDHSD17B10GAA | |
| SCHEMBL7121392 | 0.79 | KDM4E (0.65) | KDM4EALDH1A1HPGDHSD17B10GAA | |
| SCHEMBL17505210 | 0.79 | ALDH1A1 (0.65) | KDM4EALDH1A1HPGDHSD17B10GAA | |
| SCHEMBL7116460 | 0.79 | ALDH1A1 (0.65) | KDM4EALDH1A1HPGDHSD17B10GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070148185-A1 | Novel therapeutic target for protozoal diseases | VIRGINIA POLYTECHNIC INSTITUTE AND STATE UNIVERSITY | 2007-06-28 | — | — | US | claimed |
| WO-2007047579-A2 | A NOVEL THERAPEUTIC TARGET FOR PROTOZOAL DISEASES | VIRGINIA TECH INTELLECTUAL PROPERTIES, INC. (US) | 2007-04-26 | — | — | WO | claimed |
| US-20030069271-A1 | Quinolone compounds for use in treating viral infections | SMITHKLINE BEECHAM CORPORATION | 2003-04-10 | — | — | US | disclosed |
| EP-1244629-A2 | QUINOLONE COMPOUNDS FOR USE IN TREATING VIRAL INFECTIONS | GLAXO GROUP LIMITED (GB) | 2002-10-02 | — | — | EP | disclosed |
| WO-2001046150-A2 | QUINOLONE COMPOUNDS FOR USE IN TREATING VIRAL INFECTIONS | GLAXO GROUP LIMITED (GB) | 2001-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030069271-A1 | Quinolone compounds for use in treating viral infections | IRF3, MAVS, NQO2 | KDM4E 3240/4885ALDH1A1 1742/4885HPGD 702/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.